Top

Published in:

01-05-2006 | Original Article

Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management

Authors: Jane M. Simoni, Ann E. Kurth, Cynthia R. Pearson, David W. Pantalone, Joseph O. Merrill, Pamela A. Frick

Published in: AIDS and Behavior | Issue 3/2006

Abstract

A review of 77 studies employing self-report measures of antiretroviral adherence published 1/1996 through 8/2004 revealed great variety in adherence assessment item content, format, and response options. Recall periods ranged from 2 to 365 days (mode=7 days). The most common cutoff for optimal adherence was 100% (21/48 studies, or 44%). In 27 of 34 recall periods (79%), self-reported adherence was associated with adherence as assessed with other indirect measures. Data from 57 of 67 recall periods (84%) indicated self-reported adherence was significantly associated with HIV-1 RNA viral load; in 16 of 26 (62%), it was associated with CD4 count. Clearly, the field would benefit from item standardization and a priori definitions and operationalizations of adherence. We conclude that even brief self-report measures of antiretroviral adherence can be robust, and recommend items and strategies for HIV research and clinical management.

Alcoba, M., Cuevas, M. J., Perez-Simon, M. R., Mostaza, J. L., Ortega, L., Ortiz de Urbina, J., et al. (2003). Assessment of adherence to triple antiretroviral treatment including indinavir: Role of the determination of plasma levels of indinavir. Journal of Acquired Immune Deficiency Syndromes, 33(2), 253–258.PubMed

Aloisi, M. S., Arici, C., Balzano, R., Noto, P., Piscopo, R., Filice, G., et al. (2002). Behavioral correlates of adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl 3), S145–S148.PubMed

Altice, F. L., Mostashari, F., and Friedland, G. H. (2001). Trust and the acceptance of and adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 28(1), 47–58.PubMed

Ammassari, A., Antinori, A., Aloisi, M. S., Trotta, M. P., Murri, R., Bartoli, L., et al. (2004). Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics, 45(5), 394–402.PubMed

Antinori, A., Cozzi-Lepri, A., Ammassari, A., Trotta, M. P., Nauwelaers, D., Hoetelmans, R., et al. (2004). Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antiviral Therapy, 9(2), 291–296.PubMed

Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C. J., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33(8), 1417–1423.PubMed

Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357–366.PubMed

Bangsberg, D. R., Bronstone, A., and Hofmann, R. (2002). A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care, 14(1), 3–15.PubMed

Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., Perry, S., et al. (2003). High levels of adherence do not prevent accumulation of HIV drug resistanc mutations. AIDS, 17(13), 1925–1932.PubMed

Bangsberg, D. R., Hecht, F. M., Clague, H., Charlebois, E. D., Ciccarone, D., Chesney, M., et al. (2001). Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 26(5), 435–442.PubMed

Bangsberg, D. R., Moss, A. R., and Deeks, S. G. (2004). Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 53(5), 696–699.PubMed

Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., Perry, S., et al. (2003). High levels of adherence do not prevent accumulation of HIV drug resistant mutations. AIDS, 17, 1925–1932.PubMed

Barroso, P. F., Schechter, M., Gupta, P., Bressan, C., Bomfim, A., and Harrison, L. H. (2003). Adherence to antiretroviral therapy and persistence of HIV RNA in semen. Journal of Acquired Immune Deficiency Syndromes, 32(4), 435–440.PubMed

Bartlett, J. A. (2002). Addressing the challenges of adherence. Journal of Acquired Immune Deficiency Syndromes, 29(Suppl 1), S2–S10.PubMed

Bartlett, J. G., and Gallant, J. E. (2004). Medical management of HIV infection (2004 ed.). Baltimore, MD: Johns Hopkins Medicine Health Publishing Business Group.

Bova, C. A., Fennie, K. P., Knafl, G. J., Dieckhaus, K. D., Watrous, E., and Williams, A. B. (2005). Use of electronic monitoring devices to measure antiretroviral adherence: Practical considerations. AIDS and Behavior, 9(1), 103–110.PubMed

Brigido, L. F., Rodrigues, R., Casseb, J., Oliveira, D., Rossetti, M., Menezes, P., et al. (2001). Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care and STDS, 15(11), 587–593.PubMed

Caplan, R. D., Harrison, R. V., Wellons, R. V., and Frech, J. R. P. (1980). Social support and patient adherence: Experimental and survey findings. Ann Arbor, MI: Survey Research Center, University of Michigan.

Carrieri, P., Cailleton, V., Le Moing, V., Spire, B., Dellamonica, P., Bouvet, E., et al. (2001). The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndromes, 28(3), 232–239.PubMed

Carrieri, M. P., Raffi, F., Lewden, C., Sobel, A., Michelet, C., Cailleton, V., et al. (2003). Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: A 3-year follow-up study. Antiviral Therapy, 8(6), 585–594.PubMed

Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., and McAuliffe, T. L. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 19(2), 124–133.PubMed

Cederfjall, C., Langius-Eklof, A., Lidman, K., and Wredling, R. (2002). Self-reported adherence to antiretroviral treatment and degree of sense of coherence in a group of HIV-infected patients. AIDS Patient Care and STDS, 16(12), 609–616.PubMed

Cingolani, A., Antinori, A., Rizzo, M. G., Murri, R., Ammassari, A., Baldini, F., et al. (2002). Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS, 16(3), 369–379.PubMed

Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12(3), 255–266.PubMed

Cohn, S. E., Kammann, E., Williams, P., Currier, J. S., and Chesney, M. A. (2002). Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in acquired immunodeficiency syndrome. Clinical Infectious Diseases, 34(8), 1129–1136.PubMed

DiMatteo, M. R. (2004). Variations in patients’ adherence to medical recommendations: A quantitative review of 50 years of research. Medical Care, 42(3), 200–209.PubMed

Dorz, S., Lazzarini, L., Cattelan, A., Meneghetti, F., Novara, C., Concia, E., et al. (2003). Evaluation of adherence to antiretroviral therapy in Italian HIV patients. AIDS Patient Care and STDs, 17(1),33.PubMed

Duong, M., Piroth, L., Peytavin, G., Forte, F., Kohli, E., Grappin, M., et al. (2001). Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: Relationship to virologic response. Clinical Infectious Diseases, 33(3), 386–392.PubMed

Duran, S., Peytavin, G., Carrieri, P., Raffi, F., Ecobichon, J. L., Pereira, E., et al. (2003). The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination. AIDS, 17(7), 1096–1099.PubMed

Duran, S., Saves, M., Spire, B., Cailleton, V., Sobel, A., Carrieri, P., et al. (2001). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS, 15(18), 2441–2444.PubMed

Duran, S., Solas, C., Spire, B., Carrieri, M. P., Fuzibet, J. G., Costagliola, D., et al. (2001). ‘Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?’ A comparison between patients’ self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS, 15(8), 1075–1077.PubMed

Eldred, L., Wu, A., Chaisson, R., and Moore, R. (1998). Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18(2), 117–125.PubMed

Fong, O. W., Ho, C. F., Fung, L. Y., Lee, F. K., Tse, W. H., Yuen, C. Y., et al. (2003). Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Medicine, 4(2), 133–138.PubMed

Gao, X., Nau, D., Rosenbluth, S., Scott, V., and Woodward, C. (2000). The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care, 12(4), 387–398.PubMed

Garcia de Olalla, P., Knobel, H., Carmona, A., Guelar, A., Lopez-Colomes, J. L., and Cayla, J. A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 30, 105–110.PubMed

Geletko, S. M., Segarra, M., Mayer, K. H., Fiore, T. C., Bettencourt, F. A., Flanigan, T. P., et al. (1996). Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. Antimicrobial Agents and Chemotherapy, 40(6), 1338–1341.PubMed

Gifford, A., Bormann, J., Shively, M., Wright, B., Richman, D., and Bozzette, S. (2000). Predictors of self-reported adherence and plasma HIV concentrates in patients on multi drug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes, 23(5), 386–395.PubMed

Giordano, T. P., Guzman, D., Clark, R., Charlebois, E. D., and Bangsberg, D. R. (2004). Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clinical Trials, 5(2), 74–79.PubMed

Godin, G., Gagne, C., and Naccache, H. (2003). Validation of a self-reported questionnaire assessing adherence to antiretroviral medication. AIDS Patient Care and STDs, 17(7), 325.PubMed

Golin, C. E., Liu, H., Hays, R. D., Miller, L. G., Beck, C. K., Ickovics, J., et al. (2002). A prospective study of predictors of adherence to combination antiretroviral medication. Journal of General Internal Medicine, 17(10), 756–765.PubMed

Gordillo, V., del Amo, J., Soriano, V., and Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13(13), 1763–1769.PubMed

Gordis, L. (1979). Conceptual and methodologic problems in measuring patient compliance. In D. W. T. R. B. Haynes and D. L. Sackett (Eds.), Compliance in health care (pp. 23–48). Baltimore, MD: Johns Hopkins University.

Goujard, C., Bernard, N., Sohier, N., Peyramond, D., Lançon, F., Chwalow, J., et al. (2003). Impact of a patient education program on adherence to HIV medication: A randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes, 34(2), 191–194.PubMed

Grossberg, R., Zhang, Y., and Gross, R. (2004). A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. Journal of Clinical Epidemiology, 57(10), 1107–1110.PubMed

Haubrich, R. H., Little, S. J., Currier, J. S., Forthal, D. N., Kemper, C. A., Beall, G. N., et al. (1999). The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS, 13, 1099–1107.PubMed

Ho, C. F., Fong, O. W., and Wong, K. H. (2002). Patient self-report as a marker of adherence to antiretroviral therapy. Clinical Infectious Diseases, 34(11), 1534–1535.PubMed

Hogg, R., Heath, K., Bangsberg, D. R., Yip, B., Press, N., O'shaughnessy, M. V., et al. (2002). Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS, 16, 1051–1058.

Horne, R., Buick, D., Fisher, M., Leake, H., Cooper, V., and Weinman, J. (2004). Doubts about necessity and concerns about adverse effects: Identifying the types of beliefs that are associated with non-adherence to HAART. International Journal of STD AIDS, 15(1), 38–44.PubMed

Hugen, P. W., Langebeek, N., Burger, D. M., Zomer, B., van Leusen, R., Schuurman, R., et al. (2002). Assessment of adherence to HIV protease inhibitors: Comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. Journal of Acquired Immune Deficiency Syndromes, 30(3), 324–334.PubMed

Ickovics, J. (1997). Measures of adhference. Paper presented at the Adherence to New HIV Therapies: A Research Conference, Washington, DC..

Ickovics, J. R., Cameron, A., Zackin, R., Bassett, R., Chesney, M., Johnson, V. A., et al. (2002). Consequences and determinants of adherence to antiretroviral medication: Results from Adult AIDS Clinical Trials Group protocol 370. Antiviral Therapy, 7(3), 185–193.PubMed

Ingersoll, K. (2004). The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care, 16(2), 199–211.PubMed

Kimmerling, M., Wagner, G., and Ghosh-Dastidar, B. (2003). Factors associated with accurate self-reported adherence to HIV antiretrovirals. International Journal of STD AIDS, 14(4), 281–284.PubMed

Kleeberger, C. A., Phair, J. P., Strathdee, S. A., Detels, R., Kingsley, L., and Jacobson, L. P. (2001). Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 26(1), 82–92.PubMed

Kitahata, M. M., Reed, S. D., Dillingham, P. W., Van Rompaey, S. E., Young, A. A., Harrington, R. D., et al. (2004). Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. International Journal of STD AIDS, 15(12), 803–810.PubMed

Knobel, H., Alonso, J., Casado, J., Collazos, J., Gonzalez, J., Ruiz, I., et al. (2002). Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS, 16, 605–613.PubMed

Knobel, H., Guelar, A., Carmona, A., Espona, M., Gonzalez, A., Lopez-Colomes, J. L., et al. (2001). Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care and STDs, 15, 193–199.PubMed

Knobel, H., Vallecillo, G., Guelar, A., Pedrol, E., Soler, A., Carmona, A., et al. (2004). Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent, treatment-failing patients. HIV Clinical Trials, 5(2), 65–73.PubMed

Konkle-Parker, D. J. (2000). What is the best way to measure medication adherence? HIV Clinical Trials, 12(3), 11–12.

Laniece, I., Ciss, M., Desclaux, A., Diop, K., Mbodj, F., Ndiaye, B., et al. (2003). Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS, 17(Suppl 3), S103–S108.PubMedCrossRef

Le Moing, V., Chene, G., Carrieri, M. P., Alioum, A., Brun-Vezinet, F., Piroth, L., et al. (2002). Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS, 16(1), 21–29.PubMed

Le Moing, V., Chene, G., Carrieri, M. P., Besnier, J. M., Masquelier, B., Salamon, R., et al. (2001). Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. Journal of Acquired Immune Deficiency Syndromes, 27(4), 372–376.PubMed

Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134(10), 968–977.PubMed

Lucas, G. M., Cheever, L. W., Chaisson, R. E., and Moore, R. D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27(3), 251–259.PubMed

Lopez-Suarez, A., Fernandez-Gutierrez del Almo, C., Perez-Guzman, E., and Giron-Gonzalez, J. A. (1998). Adherence to the antiretroviral treatment in asymptomatic HIV-infected patients. AIDS, 12(6), 685–686.PubMed

Maggiolo, F., Ripamonti, D., Arici, C., Gregis, G., Quinzan, G., Camacho, G. A., et al. (2002). Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clinical Trials, 3(5), 371–378.PubMed

Mannheimer, S., Friedland, G., Matts, J., Child, C., and Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34(8), 1115–1121.PubMed

Martin, J., Sabugal, G. M., Rubio, R., Sainz-Maza, M., Blanco, J. M., Alonso, J. L., et al. (2001). Outcomes of a health education intervention in a sample of patients infected by HIV, most of them injection drug users: Possibilities and limitations. AIDS Care, 13(4), 467–473.PubMed

Martin-Fernandez, J., Escobar-Rodriguez, I., Campo-Angora, M., and Rubio-Garcia, R. (2001). Evaluation of adherence to highly active antiretroviral therapy. Archives of Internal Medicine, 161(22), 2739–2740.PubMed

Mathews, W. C., Mar-Tang, M., Ballard, C., Colwell, B., Abulhosn, K., Noonan, C., et al. (2002). Prevalence, predictors, and outcomes of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care and STDS, 16(4), 157–172.PubMed

Melbourne, K. M., Geletko, S. M., Brown, S. L., Willey-Lessne, C., Chase, S., and Fisher, A. (1999). Medication adherence in patients with HIV infection: A comparison of two measurement methods. The AIDS Reader, 9(5), 329–338.PubMed

Miller, L. G., and Hays, R. D. (2000). Adherence to combination antiretroviral therapy: Synthesis of the literature and clinical implications. The AIDS Reader, 10(3), 177–185.PubMed

Miller, L. G., Hays, R. D. (2000). Measuring adherence to antiretroviral medications in clinical trials. HIV Clinical Trials, 1(1), 36–46.PubMed

Moatti, J. P., Carrieri, M. P., Spire, B., Gastaut, J. A., Cassuto, J. P., and Moreau, J. (2000). Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 Study Group. AIDS, 14(2), 151–155.PubMed

Morisky, D. E., Green, L. W., and Levine, D. M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 24(1), 67–74.PubMed

Murri, R., Ammassari, A., De Luca, A., Cingolani, A., Marconi, P., Wu, A. W., et al. (2001). Self-reported nonadherence with antiretroviral drugs predicts persistent condition. HIV Clinical Trials, 2(4), 323–329.PubMed

Nieuwkerk, P., Gisolf, E., Sprangers, M., and Danner, S. (2001). Adherence over 48 weeks in an antiretroviral clinical trial: Variable within patients, affected by toxicities and independently predictive of virological response. Antiviral Therapy, 6(2), 97–103.PubMed

Nieuwkerk, P. T., and Oort, F. J. (2005). Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. Journal of Acquired Immune Deficiency Syndromes, 38(4), 445–448.PubMed

Nieuwkerk, P. T., Sprangers, M. A., Burger, D. M., Hoetelmans, R. M., Hugen, P. W., Danner, S. A., et al. (2001). Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Archives of Internal Medicine, 161(16), 1962–1968.PubMed

Oyugi, J. H., Byakika-Tusiime, J., Charlebois, E. D., Kityo, C., Mugerwa, R., Mugyenyi, P., et al. (2004). Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes, 36(5), 1100–1102.PubMed

Palepu, A., Horton, N. J., Tibbetts, N., Meli, S., and Samet, J. H. (2004). Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction, 99(3), 361–368.PubMed

Paterson, D., Potoski, B., and Capitano, B. (2002). Measurement of adherence to antiretroviral medications. Journal of Acquired Immune Deficiency Syndromes, 31, S103–S106.PubMed

Paterson, D., Swindells, S., Mohr, J., Brester, M., Vergis, E., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21–30.PubMed

Pinheiro, C. A., de-Carvalho-Leite, J. C., Drachler, M. L., and Silveira, V. L. (2002). Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: A cross-sectional study in Southern Brazil. Brazilian Journal of Medical and Biological Research, 35(10), 1173–1181.PubMed

Pradier, C., Carrieri, P., Bentz, L., Spire, B., Dellamonica, P., Moreau, J., et al. (2001). Impact of short-term adherence on virological and immunological success of HAART: A case study among French HIV-infected IDUs. International Journal of STD AIDS, 12(5), 324–328.PubMed

Raboud, J. M., Harris, M., Rae, S., and Montaner, J. S. (2002). Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Medicine, 3(2), 118–124.PubMed

Rudd, P. (1979). In search of the gold standard for compliance measurement. Archives of Internal Medicine, 139(6), 627–628.PubMed

Rudd, P., Ahmed, S., Zachary, V., Barton, C., Bonduelle, D. (1990). Improved compliance measures: Applications in an ambulatory hypertensive drug trial. Clinical Pharmacology and Therapeutics, 48(6), 676–685.PubMedCrossRef

Samet, J. H., Sullivan, L. M., Traphagen, E. T., and Ickovics, J. R. (2001). Measuring adherence among HIV-infected persons: Is MEMS consummate technology? AIDS and Behavior, 5(1), 21–30.

Schroder, K. E., Carey, M. P., and Vanable, P. A. (2003). Methodological challenges in research on sexual risk behavior: I. Item content, scaling, and data analytical options. Annals of Behavioral Medicine, 26(2), 76–103.PubMed

Schuman, P., Ohmit, E., Cohen, M., Sacks, H., et al. (2001). Prescription of and adherence to antiretroviral therapy among women with AIDS. AIDS and Behavior, 5(4), 371.

Silveira, M. P., Draschler Mde, L., Leite, J. C., Pinheiro, C. A., and da Silveira, V. L. (2002). Predictors of undetectable plasma viral load in HIV-positive adults receiving antiretroviral therapy in southern Brazil. The Brazilian Journal of Infectious Diseases, 6(4), 164–171.PubMed

Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., and Moatti, J. P. (2002). Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Social Science and Medicine, 54(10), 1481–1496.PubMed

Straka, R. J., Fish, J. T., Benson, S. R., and Suh, J. T. (1997). Patient self-reporting of compliance does not correspond with electronic monitoring: An evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy, 17(1), 126–132.PubMed

Trotta, M. P., Ammassari, A., Cozzi-Lepri, A., Zaccarelli, M., Castelli, F., Narciso, P., et al. (2003). Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS, 17(7), 1099–1102.PubMed

Turner, B. (2002). Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. The Journal of Infectious Disease, 185(Suppl 2), S143–S151.

Turner, B. J., and Hecht, F. M. (2001). Improving on a coin toss to predict patient adherence to medications. Annals of Internal Medicine, 134(10), 1004–1006.PubMed

Vincke, J., Bolton, R. (2002). Therapy adherence and highly active antiretroviral therapy: Comparison of three sources of information. AIDS Patient Care and STDS, 16(10), 487–495.PubMed

Wagner, G. J. (2002). Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care and STDS, 16(12), 599–608.PubMed

Wagner, G. J., Kanouse, D. E., Koegel, P., and Sullivan, G. (2003). Adherence to HIV antiretrovirals among persons with serious mental illness. AIDS Patient Care and STDs, 17(4), 179.PubMed

Wagner, G., and Miller, L. G. (2004). Is the influence of social desirability on patients’ self-reported adherence overrated? Journal of Acquired Immune Deficiency Syndromes, 35(2), 203–204.PubMed

Wagner, J. H., Justice, A. C., Chesney, M., Sinclair, G., Weissman, S., and Rodriguez-Barradas, M. (2001). Patient- and provider-reported adherence: Toward a clinically useful approach to measuring antiretroviral adherence. Journal of Clinical Epidemiology, 54(Suppl 1), S91–S98.PubMed

Walsh, J. C., Horne, R., Dalton, M., Burgess, A. P., and Gazzard, B. G. (2001). Reasons for non-adherence to antiretroviral therapy: Patients’ perspectives provide evidence of multiple causes. AIDS Care, 13(6), 709–720.PubMed

Walsh, J. C., Mandalia, S., and Gazzard, B. G. (2002). Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS, 16(2), 269–277.PubMed

Waterhouse, D. M., Calzone, K. A., Mele, C., Brenner, D. E. (1993). Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology, 11(6), 1189–1197.PubMed

Weiser, S., Wolfe, W., Bangsberg, D., Thior, I., Gilbert, P., Makhema, J., et al. (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes, 34(3), 281–288.PubMed

Wutoh, A. K., Brown, C. M., Kumoji, E. K., Daftary, M. S., Jones, T., Barnes, N. A., et al. (2001). Antiretroviral adherence and use of alternative therapies among older HIV-infected adults. Journal of the National Medical Association, 93(7–8), 243–250.PubMed

Wutoh, A., Elekwachi, O., Clarke-Tasker, V., Daftary, M., Powell, N., and Campusano, G. (2003). Assessment and predictors of antiretroviral adherence in older HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 33(2), S106–S114.PubMed

Title: Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management
Authors: Jane M. Simoni
Ann E. Kurth
Cynthia R. Pearson
David W. Pantalone
Joseph O. Merrill
Pamela A. Frick
Publication date: 01-05-2006
Publisher: Springer US
Published in: AIDS and Behavior / Issue 3/2006
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-006-9078-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2006

Substance Abuse and Medication Adherence Among HIV-Positive Women with Histories of Child Sexual Abuse

Monitoring Adherence to HIV Antiretroviral Therapy in Routine Clinical Practice: The Past, the Present, and the Future

Social Support, Disclosure, and Use of Antiretroviral Therapy

Utility of Self-Reported Antiretroviral Adherence: Comment on Simoni et al. (2006)

The Differential Impact of PTSD and Depression on HIV Disease Markers and Adherence to HAART in People Living with HIV

Neurocognitive Aspects of Medication Adherence in HIV-Positive Injecting Drug Users

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage